Financial Review: Nektar Therapeutics (NKTR) & Cleveland BioLabs (CBLI)

Nektar Therapeutics (NASDAQ: NKTR) and Cleveland BioLabs (NASDAQ:CBLI) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, institutional ownership and dividends.

Institutional and Insider Ownership

95.1% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 4.6% of Cleveland BioLabs shares are held by institutional investors. 6.1% of Nektar Therapeutics shares are held by insiders. Comparatively, 2.4% of Cleveland BioLabs shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Nektar Therapeutics and Cleveland BioLabs’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nektar Therapeutics -157.14% -1,223.34% -41.87%
Cleveland BioLabs -253.09% -61.18% -49.90%

Earnings and Valuation

This table compares Nektar Therapeutics and Cleveland BioLabs’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Nektar Therapeutics $133.10 million 28.38 -$154.13 million ($1.41) -17.13
Cleveland BioLabs $2.91 million 12.03 -$5.71 million ($0.66) -4.70

Cleveland BioLabs has higher revenue, but lower earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Cleveland BioLabs, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Nektar Therapeutics and Cleveland BioLabs, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nektar Therapeutics 0 1 9 0 2.90
Cleveland BioLabs 0 0 0 0 N/A

Nektar Therapeutics currently has a consensus target price of $27.11, indicating a potential upside of 12.21%. Given Nektar Therapeutics’ higher possible upside, analysts plainly believe Nektar Therapeutics is more favorable than Cleveland BioLabs.

Volatility & Risk

Nektar Therapeutics has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Comparatively, Cleveland BioLabs has a beta of 0.06, meaning that its stock price is 94% less volatile than the S&P 500.

Summary

Nektar Therapeutics beats Cleveland BioLabs on 9 of the 12 factors compared between the two stocks.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, Pain-NKTR-181 and Oncology-ONZEALD. It is developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.

About Cleveland BioLabs

Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply